HIV-1 autoreactive antibodies: are they good or bad for HIV-1 prevention?
Haynes
Barton F
BF
Duke Human Vaccine Institute, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA. hayne002@duke.edu
Nicely
Nathan I
NI
Alam
S Munir
SM
D016915:AIDS Vaccines / Q000276:immunology; D001323:Autoantibodies / Q000276:immunology*; D015704:CD4 Antigens / Q000276:immunology; D015483:HIV Antibodies / Q000737:chemistry* / Q000276:immunology*; D015658:HIV Infections / Q000276:immunology*; D015497:HIV-1 / Q000276:immunology*; D054884:Host-Pathogen Interactions; D006801:Humans; D014759:Viral Envelope Proteins / Q000276:immunology
D016915:AIDS Vaccines; D001323:Autoantibodies; D015704:CD4 Antigens; D015483:HIV Antibodies; D014759:Viral Envelope Proteins